CARM1 promotes non-small cell lung cancer progression through upregulating CCNE2 expression

Area of Science:

• Molecular Oncology
• Epigenetics
• Cancer Biology

Background:

• The molecular drivers of non-small cell lung cancer (NSCLC) tumorigenesis remain incompletely understood.
• Cyclin E2 (CCNE2) plays a role in cell proliferation, but its regulatory mechanisms in NSCLC require further investigation.

Purpose of the Study:

• To elucidate the role of CARM1 in NSCLC progression.
• To investigate the regulatory relationship between CARM1 and CCNE2 in NSCLC.

Main Methods:

• siRNA-mediated gene silencing and forced overexpression of CCNE2 in NSCLC cell lines (PC9, HCC827).
• Chromatin immunoprecipitation (ChIP) and luciferase reporter gene assays to assess CARM1's interaction with the CCNE2 promoter.
• In vitro and in vivo rescue experiments to validate the functional dependence of CARM1 on CCNE2.
• Analysis of CARM1 and CCNE2 expression levels in NSCLC patient tissues and survival data.

Main Results:

• CCNE2 silencing inhibited NSCLC cell proliferation and colony formation, while overexpression enhanced these abilities.
• CARM1 was identified as a transcriptional activator of CCNE2, recruiting to its promoter and mediating H3R17/R26 di-methylation.
• CARM1 knockdown inhibited NSCLC cell proliferation, an effect reversed by CCNE2 restoration, indicating CARM1's oncogenic function is partly mediated by CCNE2.
• CARM1 enzymatic inhibition repressed CCNE2 expression in NSCLC cells.
• Elevated CARM1 and CCNE2 expression correlated positively in NSCLC patients and were associated with shorter overall survival.

Conclusions:

• CARM1 promotes NSCLC progression through transcriptional activation of CCNE2.
• CARM1-mediated activation of CCNE2 represents a potential therapeutic target for NSCLC treatment.